We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Test Developed for Healthcare-Acquired Infections Validated

By LabMedica International staff writers
Posted on 22 Sep 2016
Print article
Image: A colorized scanning electron micrograph (SEM) depicting two rod-shaped carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteria interacting with a human neutrophil (Photo courtesy of the NIAID).
Image: A colorized scanning electron micrograph (SEM) depicting two rod-shaped carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteria interacting with a human neutrophil (Photo courtesy of the NIAID).
Healthcare-acquired infections (HAIs) kill tens of thousands of people each year and add significantly to healthcare costs. Multidrug resistant and epidemic strains are a large proportion of HAI agents, and multidrug resistant strains of Klebsiella pneumoniae, a leading HAI agent, have become an urgent public health crisis.

In the healthcare environment, patient colonization of K. pneumoniae precedes infection, and transmission via colonization leads to outbreaks. Periodic patient screening for K. pneumoniae colonization has the potential to curb the number of HAIs, which affect hundreds of thousands of patients annually and add nearly USD10 billion in associated healthcare costs.

Scientists at the Translational Genomics Research Institute (Flagstaff, AZ, USA) and their colleagues acquired isolates for target identification and assay validation, and DNA extracted from clinical specimens were acquired through collaborations with a large hospital reference laboratory. This laboratory receives specimens from ten system-wide medical centers in Arizona, and from a high volume private reference laboratory that receives specimens from regional inpatient, long-term care, and outpatient facilities.

Isolates were identified using the VITEK 2 system (bioMérieux, Marcy-l'Étoile, France). Clinical specimen types included various respiratory specimens, nasal, ear, and throat swabs, sputa, tracheal aspirates, and bronchial alveolar lavages, urine, and wound swabs or tissue. Unlike traditional assays that require growing a live culture in a laboratory setting, which adds days to the testing process and layers on cost, the new method called KlebSeq employs a technique called amplicon sequencing that identifies the presence of Klebsiella and stratifies its characteristics, such as strain type and whether it may be antibiotic resistant.

KlebSeq can be used for routine screening and surveillance, enabling healthcare staff to make more informed patient decisions, and curb outbreak situations by rapidly identifying transmissions prior to patients showing signs of infection. Classifying the type of infection in each patient would help enable an institution to decide when and which intervention procedures to enact. The study results suggest that KlebSeq would be especially helpful for high-risk patients, such as those in intensive-care units, centers specializing in bone marrow transplantation or chronically immunosuppressed patients, long-term care facilities, and travelers returning from endemic regions. The results also suggest that KlebSeq could be easily modified to detect other healthcare-acquired infectious agents, and identify those with antimicrobial resistance.

Paul Keim, PhD, Director of TGen North and senior author of the study said, “The sensitivity of KlebSeq is superior to culture-based methods. KlebSeq is an important step toward a comprehensive, yet accessible, tool for all pathogen identification and characterization.” The study was published on August 10, 2016, in the Journal of Clinical Microbiology.

Related Links:
Translational Genomics Research Institute
bioMérieux
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.